CSMD1 rs10503253 increases schizophrenia risk in a Tunisian population-group

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Schizophrenia is a complex neuropsychiatric disorder with identified genetic risk variants.
• Genome-wide association studies highlight single nucleotide polymorphisms (SNPs) like rs10503253 (CSMD1) and rs1270942 (CFB) as potential risk factors.

Purpose of the Study:

• To investigate the association between rs10503253 and rs1270942 variants and schizophrenia risk.
• To evaluate the relationship between these genetic variants and schizophrenia disease severity and clinical characteristics in a Tunisian population.

Main Methods:

• A case-control study involving 216 schizophrenia patients and 176 healthy controls.
• Genotyping of rs10503253 and rs1270942 polymorphisms using the tetra Primer Amplification Refractory Mutation System-Polymerase Chain Reaction method.
• Statistical analysis using Compare V2.1 software and Kruskal-Wallis testing for correlations.

Main Results:

• The rs10503253A allele was significantly more frequent in schizophrenia patients and correlated with higher negative PANSS scores.
• No significant association was found for rs1270942 with schizophrenia risk, but it correlated positively with higher positive PANSS scores.

Conclusions:

• Confirms the association of the CSMD1 rs10503253A allele with schizophrenia risk.
• Identifies the rs1270942 variant as a potential modifier of schizophrenia disease risk and severity.
• Suggests the importance of these genetic findings for understanding the immunogenetic background in North African populations at risk for mental disorders.